Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy.
Epstein-Barr virus
human adenovirus
polymerase chain reaction
prognosis
renal cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Oct 2020
02 Oct 2020
Historique:
received:
02
09
2020
revised:
20
09
2020
accepted:
29
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
There is growing evidence that viral infections may impact the risk and clinical course of malignancies, including solid tumors. The aim of this study was to assess the possible association of selected chronic/latent viral infections with the clinical course of renal cell carcinoma (RCC). In this prospective study we enrolled 27 patients undergoing partial or radical nephrectomy due to the histologically confirmed RCC and followed them up for one year post-operation. Isolation of the nucleic acids was performed using the NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany) from tumor tissue and using the EZ1 Virus Mini Kit v2.0 from plasma. The number of viral copies of human adenovirus (ADV), herpes simplex virus HSV-1 and HSV-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), BK virus (BKV) and John Cunningham virus (JCV) in the tissue and plasma was assessed with real-time PCR. Viral infections were diagnosed in ten patients (37.0%), including three ADV cases (11.1%) and eight EBV cases (29.6%). Infected patients tended to be significantly older (71.3 vs. 57.6 years, EBV and ADV infections are common in renal cancer patients and increase the risk of high-grade RCC presence. While there is no significant impact on short term survival, further studies are needed to assess the relevance of these findings in a long run.
Sections du résumé
BACKGROUND
BACKGROUND
There is growing evidence that viral infections may impact the risk and clinical course of malignancies, including solid tumors. The aim of this study was to assess the possible association of selected chronic/latent viral infections with the clinical course of renal cell carcinoma (RCC).
METHODS
METHODS
In this prospective study we enrolled 27 patients undergoing partial or radical nephrectomy due to the histologically confirmed RCC and followed them up for one year post-operation. Isolation of the nucleic acids was performed using the NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany) from tumor tissue and using the EZ1 Virus Mini Kit v2.0 from plasma. The number of viral copies of human adenovirus (ADV), herpes simplex virus HSV-1 and HSV-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), BK virus (BKV) and John Cunningham virus (JCV) in the tissue and plasma was assessed with real-time PCR.
RESULTS
RESULTS
Viral infections were diagnosed in ten patients (37.0%), including three ADV cases (11.1%) and eight EBV cases (29.6%). Infected patients tended to be significantly older (71.3 vs. 57.6 years,
CONCLUSIONS
CONCLUSIONS
EBV and ADV infections are common in renal cancer patients and increase the risk of high-grade RCC presence. While there is no significant impact on short term survival, further studies are needed to assess the relevance of these findings in a long run.
Identifiants
pubmed: 33023077
pii: jcm9103195
doi: 10.3390/jcm9103195
pmc: PMC7601937
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Infect Dis. 2011 Jul 15;204(2):217-23
pubmed: 21673031
APMIS. 2020 Feb;128(2):72-79
pubmed: 31990119
Curr Top Microbiol Immunol. 2015;390(Pt 1):119-48
pubmed: 26424646
Oncogene. 1996 Apr 4;12(7):1521-8
pubmed: 8622868
Nat Genet. 2020 Mar;52(3):320-330
pubmed: 32025001
J Hypertens. 2017 Jul;35(7):1333-1344
pubmed: 28157813
Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400
pubmed: 9184771
J Clin Invest. 2012 Apr;122(4):1487-502
pubmed: 22406538
Ann Diagn Pathol. 2018 Jun;34:45-49
pubmed: 29661727
Curr Opin Infect Dis. 2019 Aug;32(4):300-306
pubmed: 31116132
J Clin Invest. 1999 Dec;104(12):1673-81
pubmed: 10606621
J Med Virol. 2003 Jun;70(2):228-39
pubmed: 12696109
Eur J Cancer Prev. 1998 Aug;7(4):305-13
pubmed: 9806119
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Oncol. 2013 Jun 01;6(3):282-9
pubmed: 23730407
J Clin Oncol. 2002 Mar 1;20(5):1368-74
pubmed: 11870181
J Med Virol. 2011 Dec;83(12):2191-9
pubmed: 22012728
World J Gastrointest Pathophysiol. 2016 Nov 15;7(4):314-319
pubmed: 27895977
Oncol Lett. 2017 Aug;14(2):1855-1865
pubmed: 28789421
Oncol Rep. 2007 Jul;18(1):41-6
pubmed: 17549343
EBioMedicine. 2018 Aug;34:113-121
pubmed: 30072213
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40
pubmed: 17001014
Clin Microbiol Rev. 2014 Jul;27(3):441-62
pubmed: 24982316
Int J Cancer. 1985 Jan 15;35(1):35-42
pubmed: 2981780
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Front Endocrinol (Lausanne). 2019 Jun 12;10:355
pubmed: 31263452
Minerva Urol Nefrol. 2018 Dec;70(6):579-587
pubmed: 30160386
Eur Urol. 2016 Sep;70(3):458-66
pubmed: 26149669
Saudi J Kidney Dis Transpl. 2012 Jan;23(1):53-7
pubmed: 22237219
J Pathol. 2012 Aug;227(4):392-403
pubmed: 22431062
BJU Int. 2005 Sep;96(4):547-52
pubmed: 16104908
Cancer Sci. 2019 Apr;110(4):1132-1139
pubmed: 30697862
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
J Clin Oncol. 2014 Jun 20;32(18):1968-76
pubmed: 24821879
Gut. 2014 Feb;63(2):236-43
pubmed: 23580779
Lab Invest. 1994 Jul;71(1):73-81
pubmed: 8041121
Am J Transplant. 2011 Jun;11(6):1308-14
pubmed: 21449944
Transpl Infect Dis. 2012 Dec;14(6):555-63
pubmed: 23146063
Gastroenterology. 2009 Sep;137(3):824-33
pubmed: 19445939
Aging Male. 2020 Jun;23(2):132-138
pubmed: 29571270
Infect Agent Cancer. 2012 Dec 03;7(1):35
pubmed: 23198689
Transplantation. 2002 Jun 27;73(12):1933-6
pubmed: 12131691
Curr Opin Urol. 2017 Sep;27(5):409-414
pubmed: 28650865
Expert Rev Mol Med. 2001 Nov 15;3(28):1-20
pubmed: 14585152
J Urol. 2002 Dec;168(6):2395-400
pubmed: 12441925